PDF(Pubmed)
Abstract：
OBJECTIVE: Linking information on Japanese pharmaceutical products to global knowledge bases (KBs) would enhance international collaborative research and yield valuable insights. However, public access to mappings of Japanese pharmaceutical products that use international controlled vocabularies remains limited. This study mapped YJ codes to RxNorm ingredient classes, providing new insights by comparing Japanese and international drug-drug interaction (DDI) information using a case study methodology.
METHODS: Tables linking YJ codes to RxNorm concepts were created using the application programming interfaces of the Kyoto Encyclopedia of Genes and Genomes and the National Library of Medicine. A comparative analysis of Japanese and international DDI information was thus performed by linking to an international DDI KB.
RESULTS: There was limited agreement between the Japanese and international DDI severity classifications. Cross-tabulation of Japanese and international DDIs by severity showed that 213 combinations classified as serious DDIs by an international KB were missing from the Japanese DDI information.
CONCLUSIONS: It is desirable that efforts be undertaken to standardize international criteria for DDIs to ensure consistency in the classification of their severity.
CONCLUSIONS: The classification of DDI severity remains highly variable. It is imperative to augment the repository of critical DDI information, which would revalidate the utility of fostering collaborations with global KBs.
METHODS: Tables linking YJ codes to RxNorm concepts were created using the application programming interfaces of the Kyoto Encyclopedia of Genes and Genomes and the National Library of Medicine. A comparative analysis of Japanese and international DDI information was thus performed by linking to an international DDI KB.
RESULTS: There was limited agreement between the Japanese and international DDI severity classifications. Cross-tabulation of Japanese and international DDIs by severity showed that 213 combinations classified as serious DDIs by an international KB were missing from the Japanese DDI information.
CONCLUSIONS: It is desirable that efforts be undertaken to standardize international criteria for DDIs to ensure consistency in the classification of their severity.
CONCLUSIONS: The classification of DDI severity remains highly variable. It is imperative to augment the repository of critical DDI information, which would revalidate the utility of fostering collaborations with global KBs.
摘要：
目标：将日本医药产品的信息与全球知识库（KB）联系起来将加强国际合作研究，并产生有价值的见解。然而,公众对使用国际受控词汇的日本医药产品的映射的访问仍然有限。这项研究将YJ代码映射到RxNorm成分类别，通过使用案例研究方法比较日本和国际药物-药物相互作用（DDI）信息，提供新的见解。
方法：使用京都基因和基因组百科全书和国家医学图书馆的应用编程接口创建了将YJ代码链接到RxNorm概念的表。因此，通过链接到国际DDIKB，对日本和国际DDI信息进行了比较分析。
结果：日本和国际DDI严重程度分类之间的一致性有限。按严重程度对日本和国际DDI进行的交叉制表显示，日本DDI信息中缺少213种被国际KB分类为严重DDI的组合。
结论：需要努力标准化DDI的国际标准，以确保其严重程度分类的一致性。
结论：DDI严重程度的分类仍然高度可变。必须扩大关键DDI信息的存储库，这将重新验证促进与全球KB合作的效用。
方法：使用京都基因和基因组百科全书和国家医学图书馆的应用编程接口创建了将YJ代码链接到RxNorm概念的表。因此，通过链接到国际DDIKB，对日本和国际DDI信息进行了比较分析。
结果：日本和国际DDI严重程度分类之间的一致性有限。按严重程度对日本和国际DDI进行的交叉制表显示，日本DDI信息中缺少213种被国际KB分类为严重DDI的组合。
结论：需要努力标准化DDI的国际标准，以确保其严重程度分类的一致性。
结论：DDI严重程度的分类仍然高度可变。必须扩大关键DDI信息的存储库，这将重新验证促进与全球KB合作的效用。
